Alexion Pharma (NASDAQ:ALXN) Rating Restated
In an analyst note sent to investors on today, Leerink Partners restate their Outperform rating on Alexion Pharma (NASDAQ:ALXN)’s stock. The target price would indicate a potential upside of 26.33 % from firm’s last stock price.
According to data compiled by Thomson Reuters, Alexion Pharma (NASDAQ:ALXN)’s stock is covered by 18 equity analysts across the Street, with 0 analysts giving it a Sell rating, 13 a Buy rating, while 7 consider it a Hold. The 12-month consensus target price for the stock is $187.61, which reflects an upside potential of 30.14% over the current price.
Baker Bros. Advisors Lp had the most significant stake with ownership of 6.54M shares as of Q2 2015 for 7.28% of the portfolio. Lagoda Investment Management L.P. is another bull as the institutional investor who is having 157,853 shares of Alexion Pharma or 5.82% of their portfolio. Further, Bb Biotech Ag have 5.08% of their portfolio invested in the company for 1.18M shares. The New York-based fund Healthcor Management L.P. disclosed it had bought so far a stake worth about 4.85% of the institutional investor’s stock portfolio in Alexion Pharma. The Connecticut-based fund March Altus Capital Management Lp is also positive about the stock, possessing 650,000 shares or 4.75% of their portfolio.
Alexion Pharma (NASDAQ:ALXN) Profile
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Alexion Pharma (NASDAQ:ALXN) traded up 0.07% on 13 September, hitting $144.16. A total of 283,478 shares of the company’s stock traded hands. This is down from average of 1.48M shares. Alexion Pharma has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market cap of $32.18B and a P/E ratio of 62.47.
Get the latest Alexion Pharma (NASDAQ:ALXN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post New York: Alexion Pharma (NASDAQ:ALXN)’s Stock Had Its Outperform Rating Restated at Leerink Partners in Report Issued Today. Has $182.0 Target appeared first on Octafinance.